News

MorphoSys plans US share offering

Country
Germany

MorphoSys AG has announced plans for a US share offering following a year in which its lead lymphoma antibody MOR208 received a ‘breakthrough therapy’ designation from the Food and Drug Administration and a second product based on its technology was launched by Janssen Biotech.

Dutch biotech raises $19 million for psoriasis drug

Country
Netherlands

Netherlands-based Escalier Biosciences BV has raised $19 million in a Series B financing round to bring a topical compound into the clinic for the treatment of psoriasis. The first clinical study is expected to start in mid-2018.

Tecentriq shows PFS benefit in lung cancer

Country
Switzerland

The second arm of a Phase 3 study of the checkpoint inhibitor Tecentriq (atezolizumab) in patients with advanced lung cancer has shown a progression free survival (PFS) benefit when combined with chemotherapy, according to the developer Roche.

Lundbeck builds PD franchise with Prexton acquisition

Country
Denmark

H. Lundbeck A/S is to pay €100 million upfront to buy a six-year-old biotech that is developing a small molecule drug for treating the motor symptoms of Parkinson’s disease (PD). This will broaden its neurological franchise which includes PD.

Alzheimer’s drug has effect at higher dose

Country
Germany

An experimental drug for Alzheimer’s disease that has failed in successive trials to show efficacy, demonstrated for the first time that it can reduce amyloid beta plaques in the brain at a higher dose. Gantenerumab achieved an effect at dosing of up to 1200 mg.

MorphoSys to raise R&D spending

Country
Germany

MorphoSys AG will maintain a high level of research and development spending this year as it advances its lymphoma antibody MOR208 in the clinic with a goal of getting an expedited review of the product from the US Food and Drug Administration.

Meeting Report – Joint HTA in the European Union

Country
Netherlands

If everything goes according to plan, member states of the European Union will in future use a common methodology to decide whether a new medicine or medical device is clinically effective, relative to certain benchmarks, and therefore be considered for reimbursement. This is the scenario envisioned by the European Commission under a proposed Regulation on Health Technology Assessment, which was unveiled earlier this year.

MYSTIC trial results to be later than expected

Country
United Kingdom

AstraZeneca Plc said that final data from its Phase 3 MYSTIC trial which is testing a combination immunotherapy for non-small cell lung cancer, are now expected in the second half of the year, rather than in the first half.

Autolus files for potential US IPO

Country
United Kingdom

UK-based Autolus Ltd has made a submission to the US Securities and Exchange Commission relating to a potential initial public offering of its shares. As of 8 March, the timing and terms of the potential offering had not been determined.

Ipsen moves ahead in cancer

Country
France

Ipsen SA reported its best annual results so far in 2017 with consolidated revenue rising by 20.4% to €2.0 billion and operating profit gaining 30.4% to €397.2 million. The French company’s market value rose by 45.5% for the year to €8.3 billion, reflecting the strong performance.